Pfizer's big blockbuster Xeljanz flunks its post-marketing safety study, renewing harsh questions for JAK class
When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
